New York Regulators Investigate Cadaver-Derived Filler alloClae Distribution Without License
New York state health officials are investigating Tiger Aesthetics for allegedly distributing alloClae, an FDA-regulated injectable filler made from sterilized cadaver fat, without proper state licensing. The company claims the product is legally sold nationwide and that state law doesn't require licenses for sterilized products, while regulators say Tiger engaged in a year-long scheme to smuggle the product into the state. The case highlights a regulatory gray area between FDA oversight and state licensing requirements for novel medical products.
Tiger Aesthetics, the sole manufacturer of alloClae, began distributing the cadaver-derived filler to select plastic surgeons in 2024, where it gained popularity for procedures like breast augmentation and hip dip smoothing without general anesthesia. New York state health officials filed a lawsuit in May alleging the company distributed the product without obtaining required state distribution licenses, with at least one doctor's supply seized. Tiger disputes the state's authority, arguing alloClae is regulated by the FDA under rules that don't require premarket approval and that state law doesn't mandate licenses for sterilized products. Despite a June pause in distribution announced by the company, multiple surgeons' offices continue advertising the product, which can cost up to $100,000 per procedure. Legal experts suggest the case could go either way, depending on whether other states have raised similar concerns and how courts interpret the regulatory jurisdiction between federal and state authorities.
What's missing
The article does not provide information about alloClae's safety profile, clinical efficacy data, or whether any adverse events have been reported to the FDA or state health authorities. Additionally, the specific FDA regulatory pathway and approval status for alloClae is not detailed beyond stating it doesn't require premarket approval.
What different sources said
- Business InsiderLeft
A hot new filler made from dead people's fat is being 'smuggled' into New York, state regulators say
Related
FDA Updates Alli Label to Warn of Rare but Potentially Fatal Kidney Problems
The FDA has approved updated labeling for Alli, an over-the-counter weight loss pill, to warn of rare risks including acute kidney injury, kidney stones, and oxalate nephropathy. The agency now instructs people with kidney disease history to consult a doctor before use and directs all users to stop taking the drug if they experience symptoms like back pain, blood in urine, or leg swelling. This warning is significant because Alli is the only OTC weight loss medication available in the U.S., and approximately 40 million people have used orlistat (Alli's generic form) since its approval in 1999.
AI's Growing Role in Clinical Trials Depends on Skilled Implementation
Artificial intelligence is being integrated across clinical trials for drug discovery, patient selection, protocol design, and data management. The technology shows particular promise for rare disease research through AI-powered artificial twins that could replace traditional placebo controls. However, experts emphasize that AI tools are only effective when properly implemented by trained personnel who prioritize patient outcomes over technological advancement.
US Suicide Deaths Fall Nationally, but Several States See Sharp Increases
National suicide deaths fell 3% between 2023-2024, but New Hampshire experienced a 12% increase, with Iowa, Connecticut, and South Carolina also seeing double-digit or near double-digit rises. The report from Trust for America's Health notes that rural areas tend to have higher suicide rates, though the specific causes of state-level variations remain unclear. Regional disparities persist, with the Midwest showing the highest suicide rates and the Northeast the lowest, though all regions have increased substantially since 2004.